ArticleACR open rheumatology2026
Distinct Interferon and Intracellular Signaling Signatures in Systemic Lupus Erythematosus and Dermatomyositis by Integrative Transcriptomic and Proteomic Analysis.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTranscript and protein abundance data were measured to compare biologic pathway effects in the peripheral blood of patients diagnosed with systemic lupus erythematosus (SLE) and dermatomyositis (DM) who receive immunosuppressive therapies.
methodsExpression data from the peripheral blood of patients with SLE (n = 41) and DM (n = 14) were obtained using one transcriptomic and two proteomic platforms and compared with matched healthy control subjects. Regulatory effects were integrated across the three platforms to assess biologic pathways and downstream signaling, within and across disease cohorts.
resultsExpressions of 973 gene loci were altered overall, with 67 genes shared in SLE and DM, including interferon (IFN) markers ISG15, CXCL10, OAS1, and STAT1, and other markers of cell adhesion, immune signaling, and apoptosis. A total of 24 of 32 (75%) pathways were shared in SLE and DM, including granulocyte adhesion, immune cell migration, acute-phase response, apoptosis, and L1CAM signaling. However, SLE peripheral blood exhibited distinctive activation of Type I IFN through increased ligand-receptor interactions not widely elevated in DM. Blood from patients with DM distinctly showed substantially increased expression of intracellular kinases and associated downstream signaling molecules.
conclusionUsing a multienrichment analytic approach that integrated multiple transcriptomics and proteomics platforms, common underlying immune pathways were identified in SLE and DM. Additionally, two distinctive molecular mechanisms persisted in each condition: IFN signaling was distinctly up-regulated in patients with longstanding SLE, whereas intracellular signaling, particularly kinases, were unique to DM. These shared and distinct findings highlight potential therapeutic opportunities driven by underlying molecular mechanisms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.